Tat-CIRP is a peptide inhibitor of the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP).1 It binds to MD-2 and disrupts the interaction between MD-2 and CIRP in co-immunoprecipitation assays. In vivo, Tat-CIRP (10 and 20 mg/kg) reduces infarct volume in a mouse model of stroke induced by middle cerebral artery occlusion (MCAO). It also reduces infarct volume and decreases the time to pick up and withdraw food with the stroke-affected arm in a rhesus monkey model of thrombosis-induced stroke.WARNING This product is not for human or veterinary use.
